WISDOM
14.10.2021 18:02:04 CEST | Business Wire | Press release
Wisdom – the social audio app built to democratise mentorship – is now live in the UK, the US, Australia, and Canada. Founded by Dayo Akinrinade, the Wisdom app is an inclusive space where diverse people come together to have conversations that matter.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211014005070/en/
On a mission to become the next big social audio community, Wisdom taps into the intimacy and authenticity provided by the emerging medium. Drop-in social audio is transforming social networking because it takes interactions and conversations back to their roots. As the oldest medium, and one that is the most “human” of all societal interactions, audio is the antithesis of the heavily filtered nature of today’s visual-led apps and one which helps amplify voices of all groups and communities.
Wisdom is the latest app to launch in the white hot social audio market. Unlike other social audio applications, like Clubhouse, Wisdom is designed from the ground up to promote conversations that matter: conversations of substance on a topic of importance. Members can chat live with experts in dozens of topics from parenting, fitness, and dating to startups, mental health, and beauty. They can listen live or playback the recordings in their own time.
In Wisdom, when a mentor starts a talk, listeners can queue up to ask questions. A timer keeps the conversation moving so no one guest can monopolise the conversation; making sure all voices are heard. Inspired by Tiktok, Wisdom leverages an algorithm-first design that quickly learns what members like to listen to. Talk recommendations are made by a deep-learning neural network.
Dayo Akinrinade, founder and CEO of Wisdom, said : “I founded Wisdom to democratise access to mentorship. During my time at OneTech , London's largest diversity in startups programme, I noticed that diverse individuals from underrepresented groups lack access to mentoring. I also personally experienced how impossible it is to use platforms like LinkedIn for mentoring. The inboxes of experts are inundated with “pick your brain” requests which end up ignored unless the request is via a warm introduction, which is itself a crystallisation of systemic inequality.”
A global platform for mentorship
Connecting with others in a meaningful way has been proven to make people happier, with deep conversations with strangers more enjoyable than small talk. Wisdom will cultivate this, with thousands of people already signed up as mentors, making it the largest platform for mentorship in the world. These experts will be able to use Wisdom to share their knowledge, interact directly with their audience and give back while getting on the ground floor of the next big social audio community.
Though the platform will be free to members, as part of its mission to democratise mentorship, Wisdom will also empower its mentors through monetisation tools so they can grow their own businesses. Monetisation features will be added to Wisdom later this year.
Akinrinade added: “Consider that Masterclass has no more than hundreds of experts on its platform and does not allow deep interactions and is not free. With Wisdom, we are building something very different. Ultimately what we are building with Wisdom is a new social graph … the Mentor Graph. This is not a messy ‘talk graph’ of anyone on any topic but a social graph of the people who can help jumpstart a career, or change a life for the better. People today hunger for conversations that matter. We believe Wisdom is the platform where these conversations can live.”
The Wisdom app is available for download today for iPhone. Android is coming soon.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005070/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
